Antiretroviral resistance in HIV
From IDWiki
- Genotyping sequences reverse transcriptase, integrase, and protease
- Resistance point mutations names as wild-type amino acid, position, and mutant amino acid (e.g. K 103 N)
- Bulk sequencing can only detect mutations that represent >20% of HIV
| Drug | Mutation | Notes |
|---|---|---|
| NRTIs | ||
| 69 insertion complex multi-NRTI resistance | M 41 L | |
| A 62 V | ||
| * 69 insert | ||
| K 70 R | ||
| L 210 W | ||
| T 215 Y F | ||
| K 219 Q E | ||
| 151 complex multi-NRTI resistance | A 62 V | |
| V 75 I | ||
| F 77 L | ||
| F 116 Y | ||
| Q 151 M | ||
| Thymidine analogue-associated mutations (TAMs) multi-NRTI resistance | M 41 L | resistance to AZT and d4T; resistance to others is proportional to the number of TAMs |
| D 67 N | ||
| K 70 R | ||
| L 210 W | ||
| T 215 Y F | ||
| K 219 Q W | ||
| Abacavir | K 65 R E N | |
| L 74 V | ||
| Y 115 F | ||
| M 184 V | common; can still use TDF, AZT | |
| Emtricitabine | K 65 R E N | |
| M 184 V I | common; can use ABC (if M184I), TDF, AZT; can still use FTC in combination with TDF or TAF | |
| Lamivudine | K 65 R E N | |
| M 184 V I | common; can use ABC (if M184I), TDF, AZT; can still use 3TC in combination with TDF or TAF | |
| Tenofovir | K 65 R E N | |
| K 70 E | ||
| Zidovudine | M 41 L | |
| D 67 N | ||
| K 70 R | ||
| L 210 W | ||
| T 215 Y F | ||
| K 219 Q E | ||
| NNRTIs | ||
| Doravirine | V 106 A I M T | |
| Y 188 C L H | ||
| G 190 E | ||
| P 225 H | ||
| F 227 C L R | ||
| M 230 L | ||
| L 234 I | ||
| Efavirenz | L 100 I | |
| K 101 P | ||
| K 103 N S | ||
| V 106 M | ||
| V 108 I | ||
| Y 181 C I | ||
| Y 188 L | ||
| G 190 S A | ||
| P 225 H | ||
| M 230 L | ||
| Nevirapine | L 100 I | |
| K 101 P | ||
| K 103 N S | ||
| V 106 A M | ||
| V 108 I | ||
| Y 181 C I | ||
| Y 188 C L H | ||
| G 190 A | ||
| M 230 L | ||
| Rilpivirine | L 100 I | |
| K 101 E P | ||
| E 138 A G K Q R | ||
| V 179 L | ||
| Y 181 C I V | ||
| Y 188 L | ||
| H 221 Y | ||
| F 227 C | ||
| M 230 I L | ||
| Protease inhibitors | ||
| Atazanavir | L 10 I F V C | |
| G 16 E | ||
| K 20 R M I T V | ||
| L 24 I | ||
| V 32 I | ||
| L 33 I F V | ||
| E 34 Q | ||
| M 36 I L V | ||
| M 46 I L | ||
| G 48 V | ||
| I 50 L | ||
| F 53 L Y | ||
| I 54 L V M T A | ||
| D 60 E | ||
| I 62 V | ||
| I 64 L M V | ||
| A 71 V I T L | ||
| G 73 C S T A | ||
| V 82 A T F I | ||
| I 84 V | ||
| I 85 V | ||
| N 88 S | ||
| L 90 M | ||
| I 93 L M | ||
| Darunavir | V 11 I | |
| V 32 I | ||
| L 33 F | ||
| I 47 V | ||
| I 50 V | ||
| I 54 M L | ||
| T 74 P | ||
| L 76 V | ||
| I 84 V | ||
| L 89 V | ||
| INSTIs | ||
| Bictegravir | G 118 R | |
| E 138 K | ||
| G 140 S | ||
| Q 148 H | ||
| R 263 K | ||
| Cabotegravir | T 66 K | |
| G 118 R | ||
| E 138 A K T | ||
| G 140 A C R S | ||
| Q 148 H K R | ||
| S 153 F Y | ||
| N 155 H | ||
| R 263 K | ||
| Dolutegravir | G 118 R | |
| F 121 Y | ||
| E 138 A K T | ||
| G 140 A S | ||
| Q 148 H K R | ||
| N 155 H | ||
| R 263 K | ||
| Elvitegravir | T 66 I A K | |
| E 92 Q G | ||
| T 97 A | ||
| F 121 Y | ||
| S 147 G | ||
| Q 148 H K R | ||
| N 155 H | ||
| R 263 K | ||
| Raltegravir | L 74 M | |
| E 92 Q | ||
| T 97 A | ||
| F 121 Y | ||
| E 138 A K | ||
| G 140 A S | ||
| Y 143 R H C | ||
| Q 148 H K R | ||
| N 155 H | ||
| R 263 K | ||